Molecular targeted therapy using small molecular inhibitors and monoclonal antibodies targeting HER2 or VEGF has shown improved anti-cancer efficacy, especially in advanced and metastatic GC compared with traditional surgical resection, radiation and chemotherapy [42]. This evidence concerns the gene VEGFA and gastric cancer.